+ Watch ABBV
on My Watchlist
Real money pick - Dividend Aristocrats
TSA Abbott spinoff. Growth and yield.
AbbVie has a chance to beat Gilead in the race to gain approval for the first all oral Hep C treatment for the most common genotype 1.
Hep C cure and new drug pipeline
This stock will be quite volitile for the next few years, but it's pipeline is strong. If the pipeline is delivered, this will be a strong company for years to come. 2016 is the "big" year according to many analysts because of Humira patent protection loss, but this is an overhyped notion based on trends in the pharmaceutical market in general, not specifically based on the type of product it is. Since Humira is a biologic, creating a generic (bio-similar) is much more difficult to do, and much more difficult to get approved. The "patent cliff" is typically more important when it comes to small molecule drugs because generics are much easier to develop for these types of medicines. While the patent is worrysome, it's not to the extent that many analysts believe. The next few years will be crucial, though, for this young company - especially with the race with Gillead over Hepatitus C medicines.
Institutional investors have yet to buy
Fantastic dividend and growth here. This is Abbotts business
Could be in sweet spot for market performance
Some P/E ratios for comparison:BMY 33.79MRK 21.99PFE 22.24JNJ 20.50And...ABBV 12.44P/E isn't everything, but ROE and ROA are pretty outstanding as well in comparison. Yes there are worries about being reliant on one drug, but there's plenty of time to bail if nothing promising comes down the pipeline. In the meantime, revenues from Humira are increasing, which means good things for about 2 more years at least. This is a classic undervalued spinoff, despite the large size.
Happy owner in real life...value, yield and low beta.
MEDICAL SEC. result of 2/1 split from ABT last month should be good appreciation.
This is Abbott Labs all over again. I think it is going to fly. Simply my own opinion knowing we have most of the very same people running this new company.
Dividend PayoutPOSTED AT 1/11/2013 7:09:37 PMThe stock ABBV has paid out a dividend of $0.4. The starting price for your pick has been adjusted to reflect the value of this dividend payout.
My favorite dividend-paying stock: 4.7% yield and very promising early stage pipeline. I particularly like ABT-199:http://biotechstrategyblog.com/2013/01/ash-2012-abt-199-shows-promise-in-cll-and-mcl.html/
They are the hands down frontrunner in regards to treating the genotype 1 hep c patients.gilead is painting a picture of big success but if you look deeper they are using geno 2 when in reality, the hard to treat prevelent geno 1 null responders are being sent home without SVR 1 in 10 clears
This stock is gonna kick ass for a while.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions